PLSE
Pulse Biosciences Inc

1,941
Loading...
Loading...
News
all
press releases
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Zacks·22d ago
News Placeholder
More News
News Placeholder
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
Zacks·1mo ago
News Placeholder
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to present at the...
Business Wire·8mo ago
News Placeholder
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, today...
Business Wire·8mo ago
News Placeholder
Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, today announced that its nanosecond PFA...
Business Wire·8mo ago
News Placeholder
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced the late-breaking data from its Nanosecond...
Business Wire·9mo ago
News Placeholder
Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced that its nsPFA technology will be featured...
Business Wire·9mo ago
News Placeholder
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today...
Business Wire·9mo ago
News Placeholder
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to present at the...
Business Wire·9mo ago
News Placeholder
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that it intends to deliver an...
Business Wire·9mo ago

Latest PLSE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.